Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#3028 Pancreatic Neuroendocrine Neoplasms: Dissecting the Molecular Heterogeneity
Introduction: Pancreatic neuroendocrine neoplasms (PNENs) are a group of rare but biologically and clinically heterogeneous neoplasms with variable patient outcomes. Little is known about the molecular differences between PNENs and the biologic significance of such divergence.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Yang K, Kalloger S, Aird J, Lee M, Colborne S,
Keywords: Pancreatic neuroendocrine neoplasms, Exome, Transcriptome, Proteome,
Introduction: In the past, all Neuroendocrine Neoplasm (NEN) patients (pts) on long-acting somatostatin analogues (SA), had to attend local hospitals/clinics to have them administered by nurses/doctors. Recently, a “homecare service” was developed, allowing pts to have their injections delivered to their home and injections were either administered by themselves, their partner or a Specialist Nurse (SN).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Gertner J
Authors: Gertner J, McSweeney A, Furtado O'Mahony L, Quaglia E, John A,
Keywords: homecare,
Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Feuilly M
Authors: Feuilly M, Cristeau O, Clay E, François C, Whalen J,
Keywords: somatostatin analogues, economics,
Introduction: Surufatinib is a targeted inhibitor of tyrosine kinases VEGFR1, 2, & 3, FGFR1, and CSF-1R. The safety profile was favorable in 2 completed studies (NCT02133157, NCT02267967) conducted in China. A recent phase 3 placebo controlled study (NCT02588170) confirmed safety, and demonstrated superior efficacy (PFS: 9.2 v 3.8 months) of Surufatinib in Chinese pts with advanced extra-pancreatic NETs (epNET).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Dasari A, Paulson S, Sung M, Tucci C, Kauh J,
Keywords: Neuroendocrine Tumors, Pancreatic, Surufatinib,
Introduction: PET/CT imaging of patients with neuroendocrine neoplasms (NEN) 1 hour (h) post injection (pi) of 64Cu-DOTATATE has shown superiority in lesion detection when compared to other clinically available somatostatin receptor imaging (SRI) modalities.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Loft M, Johannesen H, Carlsen E, Johnbeck C, Binderup T,
Keywords: 64Cu-DOTATATE, Neuroendocrine Neoplasms, PET Imaging, Somatostatin Receptor Imaging,